John Sullivan, MD
Gastroenterology · Cleveland, OHNPI 1801153614
Payments from drug & device makers
Across 207 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$526
- Johnson & Johnson$477
- Pfizer$463
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$428
- Ardelyx, Inc.$198
- plus $370 from 14 others
What the payments were for
- Food & beverage$3,65795%
- Education$1835%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 82 | $1,378 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $526 |
| Johnson & Johnson | 17 | $477 |
| Pfizer | 22 | $463 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 28 | $428 |
| Ardelyx, Inc. | 9 | $198 |
| Lilly USA, LLC | 3 | $64 |
| Nestle Healthcare Nutrition Inc. | 3 | $59 |
| Aimmune Therapeutics, Inc. | 2 | $34 |
| Madrigal Pharmaceuticals | 1 | $34 |
| Sandoz | 2 | $32 |
| Sanofi | 1 | $27 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Bristol Myers Squibb | 1 | $17 |
| Novo Nordisk | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $13 |
| Shionogi Inc | 1 | $12 |
| Merck | 1 | $11 |
How this compares
$3,840 in reported general payments places this provider in the 55th percentile of 657 gastroenterology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mesalamine | 27 | $17,825 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 246 | $3,031 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 12 | $2,039 |
| Budesonide EcBudesonide | 21 | $1,981 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 11 | $1,771 |
| Pantoprazole Sodium | 212 | $1,646 |
| Balsalazide Disodium | 15 | $1,536 |
| Budesonide DrBudesonide | 19 | $947 |
| Dicyclomine Hcl | 29 | $914 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 46 | $910 |
| Omeprazole | 95 | $795 |
| Famotidine | 54 | $608 |
| Esomeprazole Magnesium | 18 | $268 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 14 | $167 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Cleveland
- Florian RiederCleveland$8.7M
- Pierre GholamCleveland$1.9M
- Benjamin CohenCleveland$1.9M
- Bret LashnerCleveland$628K
- Jeffry KatzCleveland$602K
- Samita GargCleveland$470K
- Stanley CohenCleveland$382K
- Katherine FalloonCleveland$339K
- Mazen IssaCleveland$329K
- Taha QaziCleveland$307K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.